Published • loading... • Updated
GLP-1 Drugs Like Ozempic Face a New Test: Multiple Sclerosis
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
GLP-1 Drugs Like Ozempic Face a New Test: Multiple Sclerosis
A new narrative review finds that GLP-1 receptor agonists like semaglutide and tirzepatide are safe and effective for weight loss in people with multiple sclerosis, but their potential as neuroprotective disease-modifying treatments remains unproven.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
